Breaking Finance News

Zacks Investment Research downgraded Rexahn Pharmaceuticals, Inc. (NYSE:RNN) to Hold in a report released today.

Yesterday Rexahn Pharmaceuticals, Inc. (NYSE:RNN) traded -0.94% lower at $0.21. The company’s 50-day moving average is $0.23 and its 200-day moving average is $0.27. The last stock close price is down -32.98% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,805,401 shares of the stock were exchanged, up from an average trading volume of 866,317

Zacks Investment Research has downgraded Rexahn Pharmaceuticals, Inc. (NYSE:RNN) to Hold in a report released on 10/12/2016.

See Chart Below

Rexahn Pharmaceuticals, Inc. (NYSE:RNN)

Rexahn Pharmaceuticals, Inc. has a 52 week low of $0.17 and a 52 week high of $0.52 The company’s market cap is currently $0.

About Rexahn Pharmaceuticals, Inc. (NYSE:RNN)

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *